**
In a troubling revelation, internal records have emerged showing that high-ranking officials from the Trump administration’s Environmental Protection Agency (EPA) held discussions with Bayer’s CEO, Bill Anderson, regarding ongoing litigation tied to the company’s glyphosate-based herbicides. This meeting, which took place on June 17, 2025, has raised alarm bells over the extent of corporate influence in US regulatory processes, particularly concerning public health risks associated with glyphosate, a chemical linked to cancer.
Meeting Documents Corporate Influence
The 17 June meeting involved top EPA officials who gathered with Bayer executives to discuss legal strategies surrounding glyphosate, particularly in light of lawsuits filed by thousands of individuals alleging that the herbicide caused their cancer. These claims assert that Bayer has consistently failed to adequately warn consumers about the potential risks associated with glyphosate products like Roundup.
Bayer’s legal strategy hinges on a critical argument: if the EPA has not mandated a cancer warning for glyphosate, then the company cannot be held liable for failing to issue such a warning. While this argument has found some traction in a single appellate court, it has been rejected by multiple other courts, including the Biden administration’s solicitor general.
EPA’s Support for Bayer’s Case
Following the June meeting, the Trump administration took significant steps to bolster Bayer’s position in the Supreme Court. In a filing dated December 1, 2025, Solicitor General D. John Sauer, appointed by Trump, urged the Supreme Court to consider Bayer’s appeal, which the court subsequently accepted, scheduling a hearing for April 27, 2026. Additionally, the White House invoked the Defense Production Act to safeguard glyphosate production and grant “immunity” to manufacturers like Bayer.
Bayer defended its actions, characterising the meeting as a routine part of the regulatory process. The company maintained that it has been forthcoming regarding its stance on glyphosate litigation, asserting that such meetings are not exclusive to them but involve various stakeholders, including non-governmental organisations.
Public Health Concerns Raised
Critics have expressed profound concern over the implications of this meeting and the administration’s subsequent actions. Nathan Donley, Director of Environmental Health Science at the Centre for Biological Diversity, asserted that the meeting exemplifies the undue influence that corporate interests wield over government decisions that directly impact public health. He stated, “It’s becoming abundantly clear that the political appointees at the EPA are more invested in protecting pesticide company profits than the health of Americans.”
Legal experts have echoed these sentiments, highlighting the disparity in access to regulatory officials. Whitney Di Bona, a consumer safety advocate, questioned whether the EPA afforded similar opportunities for dialogue to the countless individuals who allege they have suffered health consequences from glyphosate products. Naomi Oreskes, a Harvard professor, pointed out that such high-level meetings between corporate leaders and government officials reinforce a pattern of privileged access that favours industry interests over those of ordinary citizens.
The Broader Context of Regulatory Relationships
Zen Honeycutt, founder of Moms Across America, underscored a troubling trend of coercion by chemical companies over regulatory agencies. She noted that, despite her organisation’s repeated attempts to engage with the EPA, substantive action to restrict or ban hazardous pesticides has yet to materialise. This scenario illustrates a broader issue of regulatory capture, where industry interests infiltrate governmental processes, leaving public health at risk.
Why it Matters
The implications of this meeting extend far beyond Bayer’s litigation struggles; they shine a light on the complex interplay between corporate power and regulatory oversight in the United States. As the Trump administration’s actions reveal, the prioritisation of corporate interests over public health concerns poses a serious threat to community well-being. As citizens, we must demand accountability and transparency from our regulatory agencies, ensuring that the voices of the affected are not drowned out by the interests of powerful corporations. The outcome of Bayer’s legal battles could set significant precedents for the future of environmental health and safety regulations, making it imperative for the public to remain informed and engaged.
